ADELAIDE, Australia / RankWire.AI / – In Australia, researchers have recently uncovered a molecular switch that controls the dissemination of aggressive tumors, opening up new possibilities for preventing secondary cancers. A study featured in EMBO Molecular Medicine reveals that scientists from Adelaide University and the Olivia Newton-John Cancer Research Institute have shown that boosting levels of a key regulatory molecule called miR-342 substantially limits tumor metastasis. These findings point to a promising new strategy for addressing triple-negative breast cancer by targeting dormant cancer cells before they develop into dangerous secondary tumors in distant organs.
Although triple-negative breast cancer makes up about 10% to 15% of the roughly 21,000 breast cancer cases diagnosed annually in Australia, it accounts for a disproportionate share of fatalities. This particular subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which renders standard hormone-targeted therapies ineffective. The research team demonstrated that when miR-342 levels decline, a cancer-promoting pathway known as E2F becomes hyperactive, enabling dormant cancer cells to spread and seed secondary tumors throughout the body.
Targeted Treatments Bring New Hope for Preventing High-Risk Metastasis
In experimental models, researchers observed that restoring miR-342 levels led to a significant reduction in the spread of cancer cells to distant organs. Additionally, they identified that palbociclib, an existing CDK4/6 inhibitor drug already approved for hormone receptor-positive breast cancers, effectively suppressed metastatic tumor growth in models with low miR-342 expression. These results suggest that measuring miR-342 could enable clinicians to repurpose current drugs for high-risk patient populations.
Associate Professor Philip Gregory, co-senior author from Adelaide University’s Centre for Cancer Biology, emphasized that preventing metastasis remains the key challenge in treating aggressive breast cancers. Gregory highlighted that because palbociclib targets the overactive E2F pathway, administering the drug after cancer dissemination can prevent microscopic deposits from expanding. Instead of focusing solely on reducing primary tumor size, this approach aims to stop microscopic secondary tumors from developing into life-threatening conditions.
Peer-Reviewed Preclinical Results Published in EMBO Molecular Medicine
The research team pointed out that the biological diversity of triple-negative breast cancer has historically complicated the development of universal targeted therapies. By identifying a specific biological vulnerability shared among a certain patient subgroup, this study creates a pathway toward personalized treatment strategies. As Australian scientists work to validate these findings using patient-derived models, preparations are underway for clinical trials.
Cancer specialists and research organizations across Australia welcomed these results, underscoring the critical need for expanded treatment options when initial therapies prove ineffective. The research team aims to collaborate with international clinical networks to speed up biomarker screening processes. If validated, testing for miR-342 could soon enable clinicians to identify suitable candidates for targeted CDK4/6 inhibitor treatments early in the disease course.